AAPL341.44+1.36 (+0.40%) ▲|ABBV266.37+3.17 (+1.20%) ▲|ABT109.40+2.13 (+1.98%) ▲|ACN174.59+9.93 (+6.03%) ▲|ADBE262.96+13.78 (+5.53%) ▲|AMAT445.82-30.64 (-6.43%) ▼|AMD429.30-25.32 (-5.57%) ▼|AMGN390.22-2.89 (-0.73%) ▼|AMT172.85+1.35 (+0.79%) ▲|AMZN229.02-1.84 (-0.80%) ▼|AVGO373.31-7.60 (-2.00%) ▼|AXP333.69-2.94 (-0.87%) ▼|BA211.13-10.43 (-4.71%) ▼|BAC61.70-0.92 (-1.47%) ▼|BKNG201.24+1.93 (+0.97%) ▲|BLK1,099.86+2.31 (+0.21%) ▲|BMY63.56-0.05 (-0.07%) ▼|BNY154.06-2.43 (-1.55%) ▼|BRK-B509.85-2.53 (-0.49%) ▼|C128.26-4.21 (-3.18%) ▼|CAT782.07-58.79 (-6.99%) ▼|CL92.82+0.09 (+0.10%) ▲|CMCSA24.63+0.44 (+1.80%) ▲|COF210.73-1.68 (-0.79%) ▼|COP118.14+4.04 (+3.54%) ▲|COST976.79+10.21 (+1.06%) ▲|CRM188.52+7.02 (+3.87%) ▲|CSCO114.96-0.62 (-0.54%) ▼|CVS107.31-2.03 (-1.86%) ▼|CVX192.27+4.69 (+2.50%) ▲|DE613.53-26.31 (-4.11%) ▼|DHR199.74+0.69 (+0.35%) ▲|DIS98.65-0.24 (-0.24%) ▼|DUK129.61+0.37 (+0.29%) ▲|EMR145.75-6.06 (-3.99%) ▼|FDX309.11-3.53 (-1.13%) ▼|GD388.55-4.65 (-1.18%) ▼|GE351.10-12.50 (-3.44%) ▼|GEV905.44-37.95 (-4.02%) ▼|GILD133.75-0.58 (-0.43%) ▼|GM89.81-0.49 (-0.54%) ▼|GOOG334.48+1.88 (+0.57%) ▲|GOOGL335.38+1.67 (+0.50%) ▲|GS988.61-44.73 (-4.33%) ▼|HD341.39-3.08 (-0.89%) ▼|HON241.43-5.63 (-2.28%) ▼|IBM227.53-0.02 (-0.01%) ▼|INTC83.31-2.99 (-3.46%) ▼|INTU332.80+19.81 (+6.33%) ▲|ISRG355.28-6.53 (-1.80%) ▼|JNJ267.25+0.52 (+0.20%) ▲|JPM348.09-9.23 (-2.58%) ▼|KO89.91+1.64 (+1.86%) ▲|LIN507.53-3.65 (-0.71%) ▼|LLY1,217.51-3.16 (-0.26%) ▼|LMT572.52-8.79 (-1.51%) ▼|LOW216.84-1.40 (-0.64%) ▼|LRCX253.96-15.65 (-5.80%) ▼|MA568.20+5.45 (+0.97%) ▲|MCD271.95-1.07 (-0.39%) ▼|MDLZ65.30+2.82 (+4.51%) ▲|MDT88.20+1.32 (+1.51%) ▲|META590.56-2.86 (-0.48%) ▼|MMM179.56-2.92 (-1.60%) ▼|MO75.26+0.44 (+0.59%) ▲|MRK131.41-0.41 (-0.31%) ▼|MS204.46-7.13 (-3.37%) ▼|MSFT395.45+2.10 (+0.53%) ▲|MU775.13-45.41 (-5.53%) ▼|NEE89.04-0.25 (-0.27%) ▼|NFLX73.10+0.71 (+0.97%) ▲|NKE42.61-0.45 (-1.03%) ▼|NOW116.04+5.42 (+4.90%) ▲|NVDA191.53-5.49 (-2.78%) ▼|ORCL117.23-2.73 (-2.28%) ▼|PEP144.69+1.83 (+1.28%) ▲|PFE25.26+0.01 (+0.06%) ▲|PG145.13-3.75 (-2.52%) ▼|PLTR124.95+1.42 (+1.15%) ▲|PM199.69-0.48 (-0.24%) ▼|QCOM159.78-3.10 (-1.90%) ▼|RTX216.11-2.47 (-1.13%) ▼|SBUX104.11+1.01 (+0.97%) ▲|SCHW106.44+0.47 (+0.44%) ▲|SO96.61-0.18 (-0.18%) ▼|SPG237.02+0.32 (+0.13%) ▲|T24.43-0.24 (-0.95%) ▼|TMO576.09-0.32 (-0.06%) ▼|TMUS181.16-1.23 (-0.67%) ▼|TSLA300.99-6.45 (-2.10%) ▼|TXN269.88-7.19 (-2.60%) ▼|UBER70.50-0.24 (-0.34%) ▼|UNH424.70-4.09 (-0.95%) ▼|UNP291.95-2.50 (-0.85%) ▼|UPS105.04-0.49 (-0.46%) ▼|USB63.56-0.88 (-1.36%) ▼|V373.42+6.83 (+1.86%) ▲|VZ48.09-0.11 (-0.22%) ▼|WFC84.99-1.89 (-2.17%) ▼|WMT113.93+0.83 (+0.73%) ▲|XOM157.17+4.13 (+2.70%) ▲|AAPL341.44+1.36 (+0.40%) ▲|ABBV266.37+3.17 (+1.20%) ▲|ABT109.40+2.13 (+1.98%) ▲|ACN174.59+9.93 (+6.03%) ▲|ADBE262.96+13.78 (+5.53%) ▲|AMAT445.82-30.64 (-6.43%) ▼|AMD429.30-25.32 (-5.57%) ▼|AMGN390.22-2.89 (-0.73%) ▼|AMT172.85+1.35 (+0.79%) ▲|AMZN229.02-1.84 (-0.80%) ▼|AVGO373.31-7.60 (-2.00%) ▼|AXP333.69-2.94 (-0.87%) ▼|BA211.13-10.43 (-4.71%) ▼|BAC61.70-0.92 (-1.47%) ▼|BKNG201.24+1.93 (+0.97%) ▲|BLK1,099.86+2.31 (+0.21%) ▲|BMY63.56-0.05 (-0.07%) ▼|BNY154.06-2.43 (-1.55%) ▼|BRK-B509.85-2.53 (-0.49%) ▼|C128.26-4.21 (-3.18%) ▼|CAT782.07-58.79 (-6.99%) ▼|CL92.82+0.09 (+0.10%) ▲|CMCSA24.63+0.44 (+1.80%) ▲|COF210.73-1.68 (-0.79%) ▼|COP118.14+4.04 (+3.54%) ▲|COST976.79+10.21 (+1.06%) ▲|CRM188.52+7.02 (+3.87%) ▲|CSCO114.96-0.62 (-0.54%) ▼|CVS107.31-2.03 (-1.86%) ▼|CVX192.27+4.69 (+2.50%) ▲|DE613.53-26.31 (-4.11%) ▼|DHR199.74+0.69 (+0.35%) ▲|DIS98.65-0.24 (-0.24%) ▼|DUK129.61+0.37 (+0.29%) ▲|EMR145.75-6.06 (-3.99%) ▼|FDX309.11-3.53 (-1.13%) ▼|GD388.55-4.65 (-1.18%) ▼|GE351.10-12.50 (-3.44%) ▼|GEV905.44-37.95 (-4.02%) ▼|GILD133.75-0.58 (-0.43%) ▼|GM89.81-0.49 (-0.54%) ▼|GOOG334.48+1.88 (+0.57%) ▲|GOOGL335.38+1.67 (+0.50%) ▲|GS988.61-44.73 (-4.33%) ▼|HD341.39-3.08 (-0.89%) ▼|HON241.43-5.63 (-2.28%) ▼|IBM227.53-0.02 (-0.01%) ▼|INTC83.31-2.99 (-3.46%) ▼|INTU332.80+19.81 (+6.33%) ▲|ISRG355.28-6.53 (-1.80%) ▼|JNJ267.25+0.52 (+0.20%) ▲|JPM348.09-9.23 (-2.58%) ▼|KO89.91+1.64 (+1.86%) ▲|LIN507.53-3.65 (-0.71%) ▼|LLY1,217.51-3.16 (-0.26%) ▼|LMT572.52-8.79 (-1.51%) ▼|LOW216.84-1.40 (-0.64%) ▼|LRCX253.96-15.65 (-5.80%) ▼|MA568.20+5.45 (+0.97%) ▲|MCD271.95-1.07 (-0.39%) ▼|MDLZ65.30+2.82 (+4.51%) ▲|MDT88.20+1.32 (+1.51%) ▲|META590.56-2.86 (-0.48%) ▼|MMM179.56-2.92 (-1.60%) ▼|MO75.26+0.44 (+0.59%) ▲|MRK131.41-0.41 (-0.31%) ▼|MS204.46-7.13 (-3.37%) ▼|MSFT395.45+2.10 (+0.53%) ▲|MU775.13-45.41 (-5.53%) ▼|NEE89.04-0.25 (-0.27%) ▼|NFLX73.10+0.71 (+0.97%) ▲|NKE42.61-0.45 (-1.03%) ▼|NOW116.04+5.42 (+4.90%) ▲|NVDA191.53-5.49 (-2.78%) ▼|ORCL117.23-2.73 (-2.28%) ▼|PEP144.69+1.83 (+1.28%) ▲|PFE25.26+0.01 (+0.06%) ▲|PG145.13-3.75 (-2.52%) ▼|PLTR124.95+1.42 (+1.15%) ▲|PM199.69-0.48 (-0.24%) ▼|QCOM159.78-3.10 (-1.90%) ▼|RTX216.11-2.47 (-1.13%) ▼|SBUX104.11+1.01 (+0.97%) ▲|SCHW106.44+0.47 (+0.44%) ▲|SO96.61-0.18 (-0.18%) ▼|SPG237.02+0.32 (+0.13%) ▲|T24.43-0.24 (-0.95%) ▼|TMO576.09-0.32 (-0.06%) ▼|TMUS181.16-1.23 (-0.67%) ▼|TSLA300.99-6.45 (-2.10%) ▼|TXN269.88-7.19 (-2.60%) ▼|UBER70.50-0.24 (-0.34%) ▼|UNH424.70-4.09 (-0.95%) ▼|UNP291.95-2.50 (-0.85%) ▼|UPS105.04-0.49 (-0.46%) ▼|USB63.56-0.88 (-1.36%) ▼|V373.42+6.83 (+1.86%) ▲|VZ48.09-0.11 (-0.22%) ▼|WFC84.99-1.89 (-2.17%) ▼|WMT113.93+0.83 (+0.73%) ▲|XOM157.17+4.13 (+2.70%) ▲|
22.7 C
New York
Wednesday, July 29, 2026

Tag: immune system

newssourceFORcompanyinformationcontent1releasesmarket

FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the startINDIANAPOLIS,...

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

Châtillon, France, June 8, 2026

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Châtillon, France, June 5, 2026

SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver

Clinical Study Showed Up to 48% Natural Killer Cell Increase with probiotic strain LP281VANCOUVER, BC, June 5, 2026 /PRNewswire/ -- Synbio Tech Inc. (SynbioTech),...

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026

BOSTON, June 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target...

Press Release: Sanofi launches 2026 global employee stock purchase plan

Sanofi launches 2026 global employee stock purchase plan

AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren’s Disease at EULAR 2026

- Findings demonstrate strong correlation between CD45RC expression and lymphocytic infiltration in salivary glands, supporting its potential as both an early biomarker and therapeutic...

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

BRUSSELS, Belgium and CAMBRIDGE, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced data, comprising two posters and three abstracts, at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, demonstrating the clinical profile of dapirolizumab pegol (DZP), an investigational biologic in patients with systemic lupus erythematosus (SLE).

POP Biotechnologies Secures Up to $9.7 Million in CEPI Funding

Funding to Propel POP BIO SNAP™ Nanoparticle Vaccine Platform into Phase 1 Clinical Trials in the U.S. 
Funding to Propel POP BIO SNAP™ Nanoparticle Vaccine Platform into Phase 1 Clinical Trials in the U.S.

Booking Health Announces Release of Findings on International Access to Personalized Glioblastoma Treatment in Germany

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsImmune system

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers